Phase 1 Study to Assess Safety, Tolerability, PD, PK, Immunogenicity of IV NTR-441 Solution in Healthy Volunteers and COVID-19 Patients

Healthy volunteers: Inclusion Criteria: * Male or female, non-smoker, ≥18 and ≤55 years of age, with Body Mass Index (BMI) \> 18.5 and \< 32.0 kg/m2 * Healthy with no clinically significant findings, determined by medical evaluation (medical history, physical examination, vital signs, 12-lead ECG, and clinical laboratory evaluations) at Screening * Subject is able to understand and is willing to comply with all study requirements, and willing to follow the instructions of the study staff. * Subject voluntarily agrees to participate in this study. Exclusion Criteria: * Pregnancy, nursing, and/or breastfeeding. * Study participant has a history of an anaphylactic reaction. * Subject has used an investigational drug within 30 days (or 5 half-lives whichever is longer) prior to the first dose of study drug. * Has received any prescription or nonprescription over-the-counter (except occasional use of acetaminophen, paracetamol or ibuprofen) medication, topical medications, vitamins, dietary or herbal during the last 14 days or 5 half-lives, whichever is longer. * Subject has a positive urine test for drugs of abuse at the screening visit or admission. * Regular consumption of alcohol within 6 months prior to Screening or use of illicit substances within 3 months prior to screening. * Subject has positive test for SARS-CoV-2 infection, human immunodeficiency virus (HIV), chronic or active hepatitis B, or active hepatitis C. * Donation or loss of blood or plasma within 4 weeks prior to initial dosing. * Subject has a history or current evidence of a serious and/or unstable cardiovascular, respiratory, gastrointestinal, hematologic, autoimmune, mental or other medical disorder, including cirrhosis or malignancy; a history of a psychiatric disorder that will affect the subject's ability to participate in the study. * Subject has a clinically relevant abnormal ECG; abnormal laboratory values. * Subject has hypertension. COVID-19 patients: Inclusion Criteria: * Male or female, non-smoker, ≥18 years of age. * Participant has active laboratory-confirmed SARS-CoV-2 infection. * Participant must be hospitalized for COVID-19 pneumonia. * Ability to provide informed consent personally, or by a legally acceptable representative if the participant is unable to do so. Exclusion Criteria: * Pregnancy, nursing, and/or breastfeeding. * History of an anaphylactic reaction. * In the opinion of the clinical team, progression to death is imminent and inevitable within the next 24 hours, irrespective of the provision of treatments. * Severely immune-compromised participants. * Participant known to test positive for human immunodeficiency virus (HIV), chronic or active hepatitis B, or active hepatitis C. * Any other clinical conditions that in the opinion of the Investigator would make the participants unsuitable for the study. * Prior treatment with any investigational drug therapy against coronavirus infection within 5 half-lives, prior to enrollment * Participants who have received an experimental (or, in future, potentially a licensed) immunization or remdesivir against coronavirus remain eligible. * Participation in another clinical study with the study intervention administered from 30 days or 5 half-lives whichever is longer. * Anticipated transfer to another hospital which is not a study site during the intervention period.